Ventripoint Diagnostics Ltd. (TSXV: VPT) has announced the issuance of 601,115 common shares to satisfy $72,143 in aggregate interest owed on outstanding convertible debentures, following approval from the TSX Venture Exchange. The shares are deemed priced at $0.12 each and carry a hold period of four months and one day. The transaction includes a related-party component, as certain insiders will receive a portion of the newly issued shares, making the disclosure relevant for minority shareholders monitoring dilution and governance.

Key Points

  • Ventripoint Diagnostics Ltd. (TSXV: VPT), a Toronto-based AI-powered cardiac diagnostics company
  • 601,115 common shares issued at a deemed price of $0.12 to settle $72,143 in convertible debenture interest
  • Debentures bear interest at 10% per annum payable every six months; issuances dated May 10, June 28, and December 16, 2024
  • Investors may be watching the related-party disclosure, insider share allocation, and any further debenture interest settlements

Share Issuance Terms and TSXV Approval

Ventripoint received TSX Venture Exchange approval to issue 601,115 common shares at a deemed price of $0.12 per share, settling $72,143 in cumulative interest on convertible debentures originally issued on three separate dates in 2024. The shares are subject to a statutory hold period of four months and one day from the date of issuance. The company stated the issuance will not create a control person of the corporation, an important threshold under TSXV rules that protects the broader shareholder base from disproportionate concentration of voting power.

Related-Party Transaction and MI 61-101 Exemptions

The transaction constitutes a related-party transaction under TSXV Policy 5.9 and Multilateral Instrument 61-101, as certain insiders of Ventripoint will collectively receive 48,383 of the newly issued common shares. The company disclosed it is relying on available exemptions from formal valuation and minority shareholder approval requirements under MI 61-101, citing that the corporation is not listed on a specified market and that insider participation does not exceed 25% of market capitalisation. The fair market value of the insider portion is also stated to be below the $2,500,000 threshold under the instrument.

Convertible Debenture Structure Behind the Interest Payment

The interest payment relates to convertible debentures carrying a 10% per annum interest rate, payable on a semi-annual basis. The debentures were issued across three tranches — May 10, 2024, June 28, 2024, and December 16, 2024 — reflecting a financing strategy the company employed over the past year. Settling interest obligations through share issuance rather than cash preserves working capital, though it results in incremental dilution to existing shareholders. The immediate share price impact was not clear from available public information.